Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers - Bian, Yicong; Meng, Jian; Ma, Sheng; Li, Guangze; Wang, Yuya; Li, Shaorong; Liu, Linsheng; Huang, Chenrong; Zhang, Hua; Zhong, Dafang; Miao, Liyan (British journal of clinical pharmacology, 2022)
Keywords: fuzuloparib; mass balance; metabolite profiles; PARP; pharmacokinetics; pharmacokinetics; PARP; fuzuloparib; mass balance; metabolite profiles